在非小细胞肺癌中,新辅助疗法的前沿超越了PD-L) 1剂
Marco Sposito1, Serena Eccher1, Ilaria Scaglione1
1Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and Verona University Hospital Trust, Verona, Italy.
Expert opinion on biological therapy
|September 23, 2024
概括
在早期肺癌中探索除了PD-(L) 1抑制剂之外的新疗法是有前途的. 识别预测生物标志物对于个性化新辅助/外科手术治疗策略和改善结果至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 手术瘤学手术瘤学
背景情况:
- 手术切除是可切除肺癌的标准,但化疗提供了有限的生存益处.
- 免疫检查点抑制剂 (ICI) 在晚期非小细胞肺癌 (NSCLC) 中表现出成功.
- 对使用ICI治疗NSCLC早期阶段越来越感兴趣,最近批准了新辅助/辅助设置.
研究的目的:
- 审查新辅助/外科手术后治疗方案中除了PD-L) 1抑制剂之外的替代药物的数据.
- 探索新型疗法,包括CTLA4,LAG3,TIGIT抗体,抗血管原药物和抗体-药物合物.
- 讨论分子分析和免疫表型在指导治疗中的作用.
主要方法:
- 关于新型药物和组合的现有数据的文献综述.
- 对研究早期NSCLC的新辅助/术后治疗的研究分析.
- 探索用于预测治疗疗效的生物标志物.
主要成果:
- 新型药物和组合显示出提高手术和生存结果的潜力.
- 正在开发个性化的新辅助/术后治疗策略.
- 生物标志物识别是治疗疗效的关键.
结论:
- 替代药物和新型疗法在早期肺癌治疗中表现有前途.
- 以生物标志物为指导的个性化方法对于优化新辅助/外科手术后策略至关重要.
- 需要进一步的研究才能充分阐明这些新型药物的作用.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491